EUnetHTA 21 shares draft on medicinal JCA timelines in D5.4 deliverable

By HEOR Staff Writer

July 4, 2023

The objective is to produce Joint Clinical Assessments (JCA) for medicinal products and medical devices in order to improve quality, consistency, and national adoption of the JCA. The production process will be standardized. During the production, the methodological convergence paths defined in EUnetHTA JA3 will be tested, including the PICO concept paper and the GRADE framework paper. Additionally, the new methodological guidelines developed by EUnetHTA 21, as well as revised templates and guidelines, will be tested to address challenges identified in EUnetHTA JA3.

 

Read the draft document here: on the link below

Join the discussion on July 13th, 2023. Register now via Eventbrite at https://www.eventbrite.co.uk/e/eunethta-21-htd-meeting-tickets-647889433737?aff=oddtdtcreator 

Reference url

Recent Posts

Null Link Confirmed: Prenatal Acetaminophen Autism Risk Study in Denmark

By HEOR Staff Writer

April 17, 2026

A major nationwide Danish cohort study has found no link between maternal acetaminophen use during pregnancy and autism in children. The new evidence on prenatal acetaminophen autism risk should reassure clinicians and expectant mothers, as both population-wide and sibling-controlled analyses sho...
HIV Prevention Partnerships: Expanding Access to Lenacapavir for Global Impact

By João L. Carapinha

HIV Prevention Partnerships between PEPFAR, The Global Fund, and Gilead Sciences are accelerating access to twice-yearly injectable lenacapavir for HIV pre-exposure prophylaxis (PrEP) in high-burden countries. Unprecedented Speed to Sub-Saharan Africa This additional i...
Advancing Inclusive Healthcare Strategies Through Social Impact and Sustainability

By João L. Carapinha

April 15, 2026

In this update we examine how Novartis is embedding inclusive healthcare strategies into its core business by launching ambitious long-term Social Impact and Sustainability (SI&S) targets that reach to 2040. These targets integrate innovation, access to medicines, global health, environmental...